Literature DB >> 32145892

Infection and Inflammation Imaging: Beyond FDG.

Malte Kircher1, Constantin Lapa2.   

Abstract

This review discusses nuclear imaging of inflammation using molecular probes beyond fluoro-d-glucose, is structured by cellular targets, and focuses on those tracers that have been successfully applied clinically.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCR4; Infection; Inflammation; Molecular imaging; NaF; PET; Somatostatin receptors; TSPO

Mesh：

Substances：

Year:  2020        PMID： 32145892     DOI： 10.1016/j.cpet.2019.11.004

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  5 in total

1.  Turning the heart off: give it a second try?

Authors:  Nidaa Mikail; Fabien Hyafil
Journal:  J Nucl Cardiol       Date:  2022-06-02       Impact factor: 5.952

2.  18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?

Authors:  E Guedj; M Million; P Dudouet; H Tissot-Dupont; F Bregeon; S Cammilleri; D Raoult
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-30       Impact factor: 9.236

Review 3.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10

Review 4.  In Vivo Targeting of CXCR4-New Horizons.

Authors:  Margret Schottelius; Ken Herrmann; Constantin Lapa
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

5.  Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.

Authors:  Christian Linz; Roman C Brands; Olivia Kertels; Alexander Dierks; Joachim Brumberg; Elena Gerhard-Hartmann; Stefan Hartmann; Andreas Schirbel; Sebastian Serfling; Yingjun Zhi; Andreas K Buck; Alexander Kübler; Julian Hohm; Constantin Lapa; Malte Kircher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-29       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.